The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

Authors: A. Alvarez Secord, S.N. Lewin, C.G. Murphy, S.C. Cecere, A. Barquín, F. Gálvez-Montosa, C.A. Mathews, G.E. Konecny, I. Ray-Coquard, A. Oaknin, M.J. Rubio Pérez, A. Bonaventura, E.J. Diver, S.-M. Ayuk, Y. Wang, B.R. Corr, V. Salutari

Contributors: Institut Català de la Salut, [Alvarez Secord A] Duke Cancer Institute, Duke University School of Medicine, Durham, USA. [Lewin SN] Holy Name Medical Center Regional Cancer Center, Teaneck, USA. [Murphy CG] Bon Secours Hospital Cork, Cork, Ireland. Cancer Trials Ireland, Dublin, Ireland. [Cecere SC] Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples, Italy. [Barquín A] Gynecological, Genitourinary, and Skin Cancer Unit, Hospital Universitario HM Sanchinarro, Madrid, Spain. [Gálvez-Montosa BF] Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, Immunoconjugates, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Otros calificadores::Otros calificadores::/uso terapéutico, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Antibodies, Monoclonal, Humanized, Humans, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, Maytansine, Folate Receptor 1, Aged, Ovarian Neoplasms, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Ovaris - Càncer - Tractament, Middle Aged, Progression-Free Survival, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Avaluació de resultats (Assistència sanitària), Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Neoplasm Recurrence, Local

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39617145
http://hdl.handle.net/11351/12885

High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density

Authors: Corvigno, Sara, Fernebro, Josefin, Severin-Karisson, Josefin, Mezheieusky, Artur, Martin-Bernabe, Alfonso, Fuente, Laura Martin De La, Westbom-Fremer, Sofia, Carlson, Joseph W., Klein, Christian, Kannisto, Paivi, Hedenfalk, Ingrid, Malander, Susanne, Ostma, Arne, Dahlstrand, Hanna

Contributors: Institut Català de la Salut, [Corvigno S, Martín-Bernabé A] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. [Fernebro J] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Gynecologic Oncology, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. [Severin Karlsson J] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. [Mezheieusky A] IGP, Uppsala University, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martin De La Fuente L] Department of Clinical Sciences, Division of Oncology and Pathology, Lund University and Skåne University Hospital, Lund, Sweden, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Cystadenocarcinoma::Cystadenocarcinoma, Serous, ANATOMÍA::células::células del tejido conectivo::fibroblastos::fibroblastos asociados al cáncer, CD8-Positive T-Lymphocytes, Adenocarcinoma - Prognosi, ANATOMY::Cells::Connective Tissue Cells::Fibroblasts::Cancer-Associated Fibroblasts, Cohort Studies, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::cistoadenocarcinoma::cistoadenocarcinoma seroso, Lymphocytes, Tumor-Infiltrating, Cancer-Associated Fibroblasts, Endopeptidases, Tumor Microenvironment, Humans, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Aged, Ovarian Neoplasms, Aged, 80 and over, Cancer och onkologi, ANATOMÍA::sistemas sanguíneo e inmunológico::sangre::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::sistemas sanguíneo e inmunológico::linfocitos T CD8-positivos, Serine Endopeptidases, FAP, T cell, Membrane Proteins, CD8, Fibroblasts, Middle Aged, ANATOMY::Hemic and Immune Systems::Blood::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::Hemic and Immune Systems::CD8-Positive T-Lymphocytes, Prognosis, Progression-Free Survival, Cystadenocarcinoma, Serous, Tumor microenvironment, Cèl·lules T, Gelatinases, Cancer and Oncology, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Ovaris - Càncer - Prognosi, Fibroblast, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Neoplasm Grading, High-grade serous ovarian cancer

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39914230
http://hdl.handle.net/11351/12857
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-551880

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Authors: Valabrega, Giorgio, Pothuri, Bhavana, Oaknin, Ana, Graybill, Whitney S, Sánchez, Ana Beatriz, McCormick, Colleen, Baurain, Jean-François, Tinker, Anna V, Denys, Hannelore, O'Cearbhaill, Roisin E, Hietanen, Sakari, Moore, Richard G, Knudsen, Anja Ør, de La Motte Rouge, Thibault, Heitz, Florian, Levy, Tally, York, Whitney, Gupta, Divya, Monk, Bradley J, González-Martín, Antonio

Contributors: Institut Català de la Salut, [Valabrega G] AO Ordine Mauriziano Torino and Department of Oncology, University of Torino, Torino, Italy. [Pothuri B] GOG Foundation and Departments of Obstetrics/Gynecology and Medicine, Division of Gynecologic Oncology, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Graybill WS] Medical University of South Carolina, Charleston, SC, USA. [Sánchez AB] Unit of Genetic Counseling in Cancer and Gynecologic Oncology, Hospital General Universitario de Elche, Elche, Spain. [McCormick C] Legacy Medical Group Gynecologic Oncology, Portland, OR, USA, Vall d'Hebron Barcelona Hospital Campus, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer

Source: Gynecol Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
GYNECOLOGIC ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Gynecologic oncology, Vol. 187, p. 128-138 (2024)

Subject Terms: Adult, Indazoles, Maintenance, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Otros calificadores::Otros calificadores::/uso terapéutico, Niraparib, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial, Article, Age, Ovarian cancer, PARP inhibitor, Maintenance Chemotherapy, Piperidines, Double-Blind Method, Humans, Aged, Ovarian Neoplasms, Aged, 80 and over, 2. Zero hunger, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Age Factors, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de poli(ADP-ribosa) polimerasas, Ovaris - Càncer - Tractament, Middle Aged, Progression-Free Survival, 3. Good health, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Avaluació de resultats (Assistència sanitària), Quality of Life, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Poly(ADP-ribose) Polymerase Inhibitors, Inhibidors enzimàtics - Ús terapèutic

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38833992
https://hdl.handle.net/11351/12053
https://fisabio.portalinvestigacion.com/publicaciones/17335
https://hdl.handle.net/2078.1/300615
https://portal.findresearcher.sdu.dk/da/publications/3b29b009-9610-427c-8bef-b977a0122ed9
https://doi.org/10.1016/j.ygyno.2024.03.009
https://hdl.handle.net/2318/1982370
https://doi.org/10.1016/j.ygyno.2024.03.009

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

Authors: Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George, Stephen Chui, Aicha Seiller, Mario Liste-Hermoso, Jenna Willis, Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray-Coquard, Linda Mileshkin

Contributors: Institut Català de la Salut, [Kristeleit R] University College London Cancer Institute, London, UK. School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK. Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK. [Leary A] Gustave Roussy, Villejuif, France. [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Redondo A] Medical Oncology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain. [George A] The Institute of Cancer Research, London, UK. Royal Marsden NHS Foundation Trust, London, UK. [Chui S] Product Development Oncology, Genentech Inc., South San Francisco, CA, USA, Vall d'Hebron Barcelona Hospital Campus

Source: Br J Cancer
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Indoles, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Triple Negative Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Poly(ADP-ribose) Polymerase Inhibitors, Antibodies, Monoclonal, Humanized, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Article, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Ovarian Neoplasms, Anticossos monoclonals - Ús terapèutic, BRCA1 Protein, Ovaris - Càncer - Tractament, Middle Aged, Mama - Càncer - Tractament, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38971950
https://hdl.handle.net/11351/11954

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

Authors: Angela Schab, Amanda Compadre, Rebecca Drexler, Megan Loeb, Kevin Rodriguez, Joshua Brill, Shariska Harrington, Carmen Sandoval, Brooke Sanders, Lindsay Kuroki, Carolyn McCourt, Andrea R. Hagemann, Premal Thaker, David Mutch, Matthew Powell, Violeta Serra, Ian S. Hagemann, Ann E. Walts, Beth Y. Karlan, Sandra Orsulic, Katherine C. Fuh, Lulu Sun, Priyanka Verma, Elena Lomonosova, Peinan Zhao, Dineo Khabele, Mary M. Mullen

Contributors: Institut Català de la Salut, [Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri, USA. Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA. [Brill J] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri, USA. [Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: J Clin Invest
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, Marcadors tumorals, FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::recombinación homóloga, CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Metals, Heavy::Platinum, Ovaris - Càncer - Tractament, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Homologous Recombination, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Recombinació genètica, Clinical Research and Public Health, Platí, COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::metales pesados::platino (metal)

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40392598
http://hdl.handle.net/11351/13394

Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Authors: Coleman, Robert L., Lorusso, Domenica, Oaknin, Ana, Cecere, Sabrina Chiara, Denys, Hannelore, Colombo, Nicoletta, van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth, Wang, Yuemei, Esteves, Brooke, Method, Michael, Matulonis, Ursula

Contributors: Institut Català de la Salut, [Coleman RL] US Oncology Research, Texas Oncology, The Woodlands, Texas, USA. [Lorusso D] Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cecere SC] Department of Experimental Uro-Gynecological Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. [Denys H] Ghent University Hospital, Ghent, Belgium. [Colombo N] European Institute of Oncology IRCCS Library, Milan, Italy. University of Milan-Bicocca, Milan, Italy, Vall d'Hebron Barcelona Hospital Campus

Source: Int J Gynecol Cancer
International Journal of Gynecological Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Immunoconjugates, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos, BEVACIZUMAB, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antibodies, Monoclonal, Humanized, 3211 Oncology and carcinogenesis, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm, Humans, Ovarian Cancer, Ovarian Neoplasms, 1112 Oncology and Carcinogenesis, Folate Receptor 1, Maytansine, Oncology & Carcinogenesis, COMBINATION, Resistència als medicaments, Original Research, Aged, Aged, 80 and over, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, 3202 Clinical sciences, Obstetrics & Gynecology, CHEMOTHERAPY, Ovaris - Càncer - Tractament, Middle Aged, OPEN-LABEL, EFFICACY, 16. Peace & justice, PHASE-III, 3. Good health, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Oncology, Drug Resistance, Neoplasm, SAFETY, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Avaluació de resultats (Assistència sanitària), Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Life Sciences & Biomedicine, ANTIBODY-DRUG CONJUGATE

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38858103
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15117
https://hdl.handle.net/11351/12019
https://lirias.kuleuven.be/handle/20.500.12942/744302
https://doi.org/10.1136/ijgc-2024-005401

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Authors: Yaniz-Galende, Elisa, Zeng, Qinghe, Bejar-Grau, Juan, Klein, Christophe, Blanc-Durand, Felix, Le Formal, Audrey, Pujade-Lauraine, Eric, Chardin, Laure, Edmond, Elodie, Marty, Virginie, Ray-Coquard, Isabelle, Joly, Florence, Ferron, Gwenael, Pautier, Patricia, Berton-Rigaud, Dominique, Lortholary, Alain, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Bonichon-Lamaichhane, Nathalie, Bello Roufai, Diana, Gantzer, Justine, Rouleau, Etienne, Genestie, Catherine, Leary, Alexandra

Contributors: Institut Català de la Salut, [Yaniz-Galende E, Le Formal A] Université Paris-Saclay, Gustave-Roussy Cancer Campus, Inserm U981, Villejuif, France. [Zeng Q, Klein C] Centre d’Histologie, d’Imagerie et de Cytométrie (CHIC), Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France. [Bejar-Grau JF] Université Paris-Saclay, Gustave-Roussy Cancer Campus, Inserm U981, Villejuif, France. Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Blanc-Durand F] Université Paris-Saclay, Gustave-Roussy Cancer Campus, Inserm U981, Villejuif, France. Departement of Medecine, Gustave-Roussy Cancer Campus, INSERM U981, Université Paris-Saclay, Villejuif, France, Vall d'Hebron Barcelona Hospital Campus, Reshape, Lab

Source: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, CD8-Positive T-Lymphocytes, Quimioteràpia combinada, Precision Medicine and Imaging, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante, Antineoplastic Combined Chemotherapy Protocols, Tumor Microenvironment, Biomarkers, Tumor, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, Hepatitis A Virus Cellular Receptor 2, Aged, Ovarian Neoplasms, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Marcadors tumorals, Forkhead Transcription Factors, Ovaris - Càncer - Tractament, Middle Aged, Neoadjuvant Therapy, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38669064
https://hdl.handle.net/11351/11682
https://hal.science/hal-05029732v1
https://doi.org/10.1158/1078-0432.ccr-23-3836

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Authors: Sköld, Camilla, Corvigno, Sara, Dahlstrand, Hanna, Enblad, Gunilla, Mezheyeuski, Artur, Sundström Poromaa, Inger, Stålberg, Karin, Tolf, Anna, Glimelius, Ingrid, Koliadi, Anthoula

Contributors: Institut Català de la Salut, [Sköld C, Enblad G] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Corvigno S, Dahlstrand H] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. [Mezheyeuski A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sundström Poromaa I] Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, Vall d'Hebron Barcelona Hospital Campus

Source: Cancer Causes Control
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, Embaràs, Progesterone receptor, Cohort Studies, Transforming Growth Factor beta1, 03 medical and health sciences, 0302 clinical medicine, Ovarian cancer, Pregnancy, FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::reproducción::embarazo, Biomarkers, Tumor, Gynaecology, Obstetrics and Reproductive Medicine, Humans, Gynekologi, obstetrik och reproduktionsmedicin, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Aged, Ovarian Neoplasms, Cancer och onkologi, Original Paper, Kirurgi, Marcadors tumorals, Relaxin, Membrane Proteins, Middle Aged, PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproduction::Pregnancy, Prognosis, Cystadenocarcinoma, Serous, Parity, FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::paridad, Cancer and Oncology, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Ovaris - Càncer - Prognosi, PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Parity, Surgery, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Neoplasm Grading, Tissue micro array, Receptors, Progesterone

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38578428
https://hdl.handle.net/11351/11839
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-547728

BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease

Authors: Marta Barber, Ariadna Boloix, Alfonso Parrilla, Mariana Köber, Laia Avilés‐Domínguez, Nora Ventosa, Lidia del Carmen Ramírez‐Morales, Asunción Perez‐Benavente, Antonio Gil‐Moreno, Eva Colàs, Juan Morote, Miguel F. Segura, Olga Méndez, Anna Santamaria

Contributors: Institut Català de la Salut, [Barber M, Parrilla A, Ramírez-Morales LC, Morote J, Méndez O, Santamaria A] Grup de Recerca Biomèdica en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Boloix A, Segura MF] Grup de Recerca de Càncer i Malalties Hematològiques Infantils, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Köber M, Avilés-Domínguez L, Ventosa N] Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain. [Perez-Benavente A, Gil-Moreno A, Colàs E] Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Clin Transl Med
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Clinical and Translational Medicine, Vol 15, Iss 4, Pp n/a-n/a (2025)

Subject Terms: Medicine (General), Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Ovaris - Càncer - Aspectes genètics, Ovaris - Càncer - Tractament, Cèl·lules - Motilitat, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::movimiento celular, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Movement, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Transdifferentiation::Epithelial-Mesenchymal Transition, Letter to the Journal, Proteïnes quinases, R5-920, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::transdiferenciación celular::transición epiteliomesenquimatosa, CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-serina-treonina cinasas

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40151910
http://hdl.handle.net/11351/13069
https://doaj.org/article/83ccbf6e617440129dfc22f9950dc15e

Procalcitonin and C‐reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian cancer (EDMOCS)

Authors: José Luis Sánchez‐Iglesias, Clara Morales‐Coma, Lucas Minig, Víctor Lago, Santiago Domingo, Gemma Mancebo, Jaime Siegrist, María Soledad Fidalgo García, Antoni Llueca, Anna Serra, Paloma Cobas Lozano, Arantza Lekuona Artola, Natalia R. Gómez‐Hidalgo, Úrsula Acosta, Roser Ferrer‐Costa, Melissa Bradbury, Assumpció Pérez‐Benavente, Antonio Gil‐Moreno, the SEGO Spain‐GOG Group

Contributors: Institut Català de la Salut, [Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A] Unitat de Ginecologia Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Morales-Coma C] Unitat de Patologia Mamària, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Minig L] Department of Gynecologic Oncology, IMED Hospital, Valencia, Spain. Department of Gynecology, CEU Cardenal Herrera University, Valencia, Spain. [Lago V] Department of Gynecology, CEU Cardenal Herrera University, Valencia, Spain. Department of Gynecologic Oncology, La Fe University Hospital, Valencia, Spain. [Domingo S] Department of Gynecologic Oncology, La Fe University Hospital, Valencia, Spain. [Mancebo G] Gynecological Cancer Multidisciplinary Unit, Hospital del Mar, Barcelona, Spain. Department of Gynecology, Universitat Pompeu Fabra, Barcelona, Spain. [Gómez-Hidalgo NR, Acosta Ú, Bradbury M] Unitat de Ginecologia Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ferrer-Costa R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Acta Obstet Gynecol Scand
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Instituto de Investigación Sanitaria La Fe (IIS La Fe)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Acta Obstetricia et Gynecologica Scandinavica, Vol 103, Iss 7, Pp 1302-1310 (2024)

Subject Terms: Adult, COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::procalcitonina, Anastomotic Leak, anastomotic leakage, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::albúminas::proteína C reactiva, CHEMICALS AND DRUGS::Biological Factors::Biomarkers, Predictive Value of Tests, Biomarkers, Tumor, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Albumins::C-Reactive Protein, Humans, Other subheadings::Other subheadings::Other subheadings::/surgery, Prospective Studies, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores, colorectal resection, Aged, Gynecological Surgery, Ovarian Neoplasms, Otros calificadores::Otros calificadores::Otros calificadores::/cirugía, Gynecology and obstetrics, Ovaris - Càncer - Cirurgia, Hormones peptídiques, Cytoreduction Surgical Procedures, Middle Aged, CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Procalcitonin, 3. Good health, ovarian cancer, C-Reactive Protein, Spain, Marcadors bioquímics, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, RG1-991, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Proteïna C reactiva, Procalcitonin, Biomarkers

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38532280
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=20708
https://hdl.handle.net/11351/11593
https://doaj.org/article/5beff900b5b74722ad22a5eb0c75286c

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

Authors: David Mutch, Athina Voulgari, Xian (Marissa) Chen, William H. Bradley, Ana Oaknin, José Alejandro Perez Fidalgo, Fernando Galvez Montosa, Antonio Casado Herraez, Robert W. Holloway, Matthew A. Powell, Malgorzata Nowicka, Gabriele Schaefer, Mark Merchant, Yibing Yan

Contributors: Institut Català de la Salut, [Mutch D] Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA. [Voulgari A] Global Product Development Clinical Science, Roche Products Ltd., Welwyn Garden City, UK. [Chen XM] Translational Medicine, Genentech, Inc., South San Francisco, California, USA. [Bradley WH] Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. [Oaknin A] Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Perez Fidalgo JA] Hospital Clínico Universitario Valencia, Biomedical Research Institute INCLIVA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Universidad Católica San Antonio de Murcia (UCAM)

Subject Terms: Ovaris - Càncer - Immunoteràpia, Adult, 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Indazoles, MKNK1, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Poly(ADP-ribose) Polymerase Inhibitors, Antibodies, Monoclonal, Humanized, Quimioteràpia combinada, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Piperidines, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Humans, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors, Aged, Platinum, Ovarian Neoplasms, Aged, 80 and over, BRCA2 Protein, MEK inhibitor, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, BRCA1 Protein, immune checkpoint blockade, Middle Aged, 3. Good health, PARP inhibitor, ovarian cancer, NF1, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Phthalazines, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Neoplasm Recurrence, Local

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38288862
https://hdl.handle.net/11351/11533
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=18114

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Authors: Nicoletta Colombo, Toon Van Gorp, Ursula A. Matulonis, Ana Oaknin, Rachel N. Grisham, Gini F. Fleming, Alexander B. Olawaiye, Dorothy D. Nguyen, Andrew E. Greenstein, Joseph M. Custodio, Hristina I. Pashova, Iulia C. Tudor, Domenica Lorusso

Contributors: Institut Català de la Salut, [Colombo N] Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy. Department of Medicine and Surgery, University Milan-Bicocca, Milan, Italy. [Van Gorp T] Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium. [Matulonis UA] Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. [Oaknin A] Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Grisham RN] Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USA. [Fleming GF] The University of Chicago, Chicago, USA, Vall d'Hebron Barcelona Hospital Campus

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Paclitaxel, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Quimioteràpia combinada, 3211 Oncology and carcinogenesis, Albumins, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, FUNCTION ITEM BANK, Oncology & Carcinogenesis, Chronic Disease, Female, Ovarian Neoplasms, Platí, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, 1103 Clinical Sciences, ORIGINAL REPORTS, Ovaris - Càncer - Tractament, 3. Good health, Oncology, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Life Sciences & Biomedicine, TAXANE, GLUCOCORTICOID-RECEPTOR EXPRESSION

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37364223
https://hdl.handle.net/11351/10535
https://lirias.kuleuven.be/handle/20.500.12942/728193
https://doi.org/10.1200/jco.22.02624

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Authors: Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore Denys, Ora Rosengarten, Manuel Rodrigues, Nikolaus de Gregorio, Jeronimo Martinez García, Edgar Petru, Roman Kocián, Ignace Vergote, Patricia Pautier, Barbara Schmalfeldt, Lydia Gaba, Stephan Polterauer, Marie-Ange Mouret Reynier, Jalid Sehouli, Cristina Churruca, Frédéric Selle, Florence Joly, Véronique D'Hondt, Émilie Bultot-Boissier, Coriolan Lebreton, Jean-Pierre Lotz, Rémy Largillier, Pierre-Etienne Heudel, Florian Heitz, J.-E. Kurtz, S. Abadie-Lacourtoisie, C. Abdeddaim, J. Alexandre, P. Augereau, D. Avenin, M. Azemar, N. Baba-Hamed, O. Bally, J. Barriere, F. Bazan, D. Berton, N. Bonichon-Lamichhane, N. Bonnin, E. Boughalem, R. Boustany Grenier, P.-E. Brachet, F. Brocard, E. Bultot-Boissier, M.A. Cappiello-Bataller, H. Castanie, L. Chaigneau, C. Chakiba, D. Chocteau-Bouju, P. Combe, A. Comte, E. Coquan, C. Costan, P. Cottu, L. Crouzet, H. Cure, J. Dauba, H. Dawood, L. De Cock, T. De La Motte Rouge, C. Debelleix, C. Delbaldo, M. Demarchi, M. Deslandres, R. Despax, V. D'Hondt, A.F. Dillies-Legrain, A. Donnadieu, C. Dubot, J.-M. Extra, M. Fabbro, C. Falandry, F. Fiteni, A. Floquet, P. Follana, J.S. Frenel, G. Freyer, D. Garbay-Decoopman, C. Gavoille, V. Girre, L. Gladieff, F. Goldwasser, A. Gratet, J. Grenier, A.-C. Hardy-Bessard, P.-E. Heudel, F. Joly, A. Jouinot, E. Kalbacher, M.-C. Kaminsky, L. Lancry-Lecomte, R. Largillier, F. Le Du, A. Leary, C. Lebreton, C. Lefeuvre-Plesse, A. Lesoin, T. L'Haridon, J. Long, A. Lortholary, J.-P. Lotz, L. Mansi, J. Martin-Babau, M. Martinez, J. Medioni, E. Meriaux, J. Meunier, L. Moïse, J.-F. Moulin, M.-A. Mouret-Reynier, M. Mousseau, P. Pautier, J. Peron, C. Perrin, T. Petit, D. Petran, F. Priou, M. Provansal, N. Raban, I. Ray-Coquard, P. Regnault De La Mothe, C. Riedl, M. Rodrigues, C. Roemer-Becuwe, R. Sabatier, F. Savinelli, C. Sebbag, F. Selle, P. Soulie, D. Spaeth, R. Sverdlin, M. Timar-David, O. Tredan, P. Tresca, V. Trillet-Lenoir, T. Valentin, Y.A. Vano, B. You, F. Heitz, H. Bronger, P. Buderath, N. De Gregorio, T. Fehm, E.-M. Grischke, M. Gropp-Meier, A. Hartkopf, C. Jackisch, M. Koegel, A. Mueller, T.-W. Park-Simon, I. Runnebaum, F. Schochter, B. Schmalfeldt, B. Schnappauf, J. Sehouli, F. Trillsch, P. Wimberger, A. Oaknin, J.D. Alarcon, S. Alonso, A. Alonso Herrero, P. Barretina, A. Casado, C. Churruca, I. Fernandez, L. Gaba, J. Garcia-Donas, S. Gonzalez, G. Marquina, J. Martinez-García, A. Redondo, D. Vicente, C. Marth, S. Aust, E. Petru, A. Reinthaller, C. Schauer, D. Cibula, I. Vergote, S. Altintas, H. Denys, E. Van Nieuwenhuysen, O. Rosengarten

Contributors: Institut Català de la Salut, [Kurtz JE] Department of Medical and Surgical Oncology & Hematology, ICANS, Strasbourg, France. [Pujade-Lauraine E] Association de Recherche sur les CAncers dont GYnécologiques (ARCAGY)-GINECO, Paris, France. [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Belin L] Biostatistics and Public Health Department, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpětriére – Charles Foix, Paris, France. [Leitner K] Gynecology and Obstetrics Department, Medical University of Innsbruck, Innsbruck, Austria. [Cibula D] Department of Obstetrics and Gynecology, General University Hospital in Prague, Charles University, Prague, Czech Republic, Vall d'Hebron Barcelona Hospital Campus, COLO, Mouniati

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
JOURNAL OF CLINICAL ONCOLOGY

Subject Terms: Cancer Research, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Metals, Heavy::Platinum, PACLITAXEL, Carcinoma, Ovarian Epithelial, B7-H1 Antigen, ATALANTE/ENGOT-ov29 Investigators, DOUBLE-BLIND, [SDV.CAN] Life Sciences [q-bio]/Cancer, 3211 Oncology and carcinogenesis, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Platí, Platinum, Ovarian Neoplasms, CARBOPLATIN, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, RECURRENT OVARIAN, PRIMARY PERITONEAL, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, 1103 Clinical Sciences, ORIGINAL REPORTS, CHEMOTHERAPY, Ovaris - Càncer - Tractament, OPEN-LABEL, 3. Good health, Bevacizumab, FALLOPIAN-TUBE, Oncology, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Quality of Life, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Neoplasm Recurrence, Local, Life Sciences & Biomedicine, COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::metales pesados::platino (metal), PLUS BEVACIZUMAB

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37643382
https://hdl.handle.net/11351/10534
https://hal.science/hal-04205951v1
https://doi.org/10.1200/jco.23.00529
https://biblio.ugent.be/publication/01HSK28902D7EA0B5Y60QD3FHP/file/01HSK28RP7D1565CHAJ7YM9TPX
http://doi.org/10.1200/jco.23.00529
https://biblio.ugent.be/publication/01HSK28902D7EA0B5Y60QD3FHP
http://hdl.handle.net/1854/LU-01HSK28902D7EA0B5Y60QD3FHP

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Authors: Moore, Kathleen, FABBRO, MICHEL, OMalley, David, Grisham, Rachel, Monk, Bradley, Van Nieuwenhuysen, Els

Contributors: Institut Català de la Salut, Grisham R Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Monk BJ Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA. Van Nieuwenhuysen E Gynecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium. Moore KN Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma, USA. Fabbro M Institut régional du Cancer de Montpellier, Montpellier, France. O’Malley DM Ohio State University Comprehensive Cancer Center Arthur. Oaknin A Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Avaluació de resultats (Assistència sanitària), Ovaris - Càncer - Tractament, Quimioteràpia combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión

File Description: application/pdf

Relation: International Journal of Gynecologic Cancer;35(11); https://doi.org/10.1136/ijgc-2024-005919; https://hdl.handle.net/11351/14034; 001337027300001

Availability: https://hdl.handle.net/11351/14034
https://doi.org/10.1136/ijgc-2024-005919

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Authors: Banerjee, Susana, Van Nieuwenhuysen, Els, D'Hondt, Veronique, Monk, Bradley, Clamp, Andrew, Aghajanian, Carol, OAKNIN, ANA

Contributors: Institut Català de la Salut, Banerjee SN The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, GTG-UK, London, United Kingdom. Van Nieuwenhuysen E University Hospitals Leuven, Leuven Cancer Institute, BGOG, Leuven, Belgium. Aghajanian C Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Weill Cornell Medical College, New York, NY. D’Hondt V Institut du Cancer de Montpellier (ICM) Val d’Aurelle Parc Euromedecine, Oncologie Médicale, GINECO, Montpellier, France. Monk BJ Florida Cancer Specialists, West Palm Beach, FL. Clamp A Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, GTG-UK, Manchester, United Kingdom. Oaknin A Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Avaluació de resultats (Assistència sanitària), Ovaris - Càncer - Tractament, Quimioteràpia combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Cystadenocarcinoma::Cystadenocarcinoma, Serous, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::cistoadenocarcinoma::cistoadenocarcinoma seroso, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada

File Description: application/pdf

Relation: Journal of Clinical Oncology;43(25); https://doi.org/10.1200/JCO-25-00112; https://hdl.handle.net/11351/13656; 001556776300001

Availability: https://hdl.handle.net/11351/13656
https://doi.org/10.1200/JCO-25-00112

Incisional Hernia in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Single-Center Retrospective Study

Authors: Míguez Medina, Marta, Luzarraga, Ana, Catalán, Sara, Angeles, Martina Aida, Bonaldo, Giulio, Acosta, Úrsula, Hernandez Fleury, Alina, Bebia, Vicente, MONREAL CLUA, SONIA, Gil-Moreno, Antonio, PEREZ BENAVENTE, ASUNCION, Sanchez Iglesias, Jose Luis

Contributors: Institut Català de la Salut, Míguez Medina M, Luzarraga A, Catalán S, Acosta Ú, Hernández-Fleury A, Monreal-Clua S, Bonaldo G, Sánchez-Iglesias JL Unitat de Ginecologia Oncològica i Patologia del Tracte Genital, Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Bebia V, Angeles MA, Gil-Moreno A, Pérez-Benavente A Unitat de Ginecologia Oncològica i Patologia del Tracte Genital, Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Ginecologia Oncològica i Patologia del Tracte Genital, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Hèrnia, Ovaris - Càncer - Cirurgia - Complicacions, DISEASES::Pathological Conditions, Signs and Symptoms::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications::Incisional Hernia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Cytoreduction Surgical Procedures, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Signs and Symptoms::Pathologic Processes::Postoperative Complications, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Other subheadings::Other subheadings::Other subheadings::/surgery, ENFERMEDADES::afecciones patológicas, signos y síntomas::afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias::eventración, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos citorreductores, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, signos y síntomas::procesos patológicos::complicaciones posoperatorias, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Otros calificadores::Otros calificadores::Otros calificadores::/cirugía

File Description: application/pdf

Relation: Cancers;17(3); https://doi.org/10.3390/cancers17030418; http://hdl.handle.net/11351/12923; 001418360600001

Availability: http://hdl.handle.net/11351/12923
https://doi.org/10.3390/cancers17030418

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test: robustness and interobserver variability of the RAD51 test

Authors: Claire JH Kramer, Alba Llop‐Guevara, Elisa Yaniz‐Galende, Benedetta Pellegrino, Natalja T ter Haar, Andrea Herencia‐Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike PG Vreeswijk

Contributors: Institut Català de la Salut, [Kramer CJ, Ter Haar NT] Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. [Llop-Guevara A, Herencia-Ropero A, Serra V] Grup de Terapèutica Experimental, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. [Yaniz-Galende E] Department of Oncology, Institute Gustave Roussy, Villejuif, France. [Pellegrino B] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy, Vall d'Hebron Barcelona Hospital Campus, Kramer, Claire Jh, Llop-Guevara, Alba, Yaniz-Galende, Elisa, Pellegrino, Benedetta, Ter Haar, Natalja T, Herencia-Ropero, Andrea, Campanini, Nicoletta, Musolino, Antonino, Bosse, Tjalling, Leary, Alexandra, Serra, Violeta, Vreeswijk, Maaike Pg

Source: J Pathol Clin Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
The Journal of Pathology: Clinical Research, Vol 9, Iss 6, Pp 442-448 (2023)

Subject Terms: high-hrade serous ovarian carcinoma, analytical validation, interobserver variability, CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, high‐hrade serous ovarian carcinoma, Ovaris - Càncer - Aspectes genètics, COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::recombinasas::rec a recombinasas::rad51 recombinasa, Pathology, Biomarkers, Tumor, RB1-214, Humans, CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Recombinases::Rec A Recombinases::Rad51 Recombinase, PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Homologous Recombination, Recombinació genètica, Homologous Recombination, Ovarian Neoplasms, Observer Variation, Brief Report, Marcadors tumorals, FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::recombinación homóloga, Reproducibility of Results, 3. Good health, homologous recombination deficiency, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, RAD51 test, biomarker, Female, Rad51 Recombinase, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37504067
https://hdl.handle.net/11351/10446
https://doaj.org/article/fba349eabeb84ca8af5db56235c061a6
https://hdl.handle.net/1887/3656239

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Authors: Stephanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo Gonzalez-Ochoa, Jeffrey P. Bruce, Derek Wong, Arnavaz Danesh, Dax Torti, Jonathan Torchia, Alexander Fortuna, Sharanjit Singh, Matthew Irving, Kayla Marsh, Bernard Lam, Vanessa Speers, Aleksandra Yosifova, Ana Oaknin, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Amit M. Oza, Trevor J. Pugh

Contributors: Institut Català de la Salut, [Lheureux S] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. [Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: BRCA2 Protein, Ovarian Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, BRCA1 Protein, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::farmacoterapia combinada, Antineoplastic Agents, Ovaris - Càncer - Aspectes genètics, Ovaris - Càncer - Tractament, Poly(ADP-ribose) Polymerase Inhibitors, Quimioteràpia combinada, 3. Good health, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Therapy, Combination, Precision Medicine and Imaging, Circulating Tumor DNA, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Humans, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Cell-Free Nucleic Acids

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37327320
https://hdl.handle.net/11351/10346

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Authors: Amanda J. Compadre, Lillian N. van Biljon, Mark C. Valentine, Alba Llop-Guevara, Emily Graham, Bisiayo Fashemi, Andrea Herencia-Ropero, Emilee N. Kotnik, Isaac Cooper, Shariska P. Harrington, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Lulu Sun, Nima Mosammaparast, Violeta Serra, Peinan Zhao, Elena Lomonosova, Dineo Khabele, Mary M. Mullen

Contributors: Institut Català de la Salut, [Compadre AJ, van Biljon LN, Valentine MC, Graham E, Fashemi B] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St Louis, Missouri. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Herencia-Ropero A] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Ovarian Neoplasms, Tumor, CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, Carcinoma, Marcadors tumorals, ICTS (Institute of Clinical and Translational Sciences), Ovaris - Càncer - Tractament, Carcinoma, Ovarian Epithelial, 3. Good health, Precision Medicine and Imaging, Ovarian Epithelial, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Medicine and Health Sciences, Biomarkers, Tumor, Humans, Female, Rad51 Recombinase, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Biomarkers, Platinum

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37097615
https://hdl.handle.net/11351/10080

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Authors: Santin, Alessandro D., Vergote, Ignace, Gonzalez-Martin, Antonio, Moore, Kathleen, Oaknin, Ana, Romero, Ignacio, Diab, Sami, Copeland, Larry J., Monk, Bradley J., Coleman, Robert L., Herzog, Thomas J., Siegel, Jonathan, Kasten, Linda, Schlicker, Andreas, Schulz, Anke, Kochert, Karl, Walter, Annette O., Childs, Barrett H., Elbi, Cem, Bulat, Iurie

Contributors: Institut Català de la Salut, [Santin AD] Yale School of Medicine, New Haven, CT, USA. [Vergote I] University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. [González-Martín A] Clinica Universidad de Navarra, Madrid, Spain. [Moore K] University of Oklahoma Health Sciences Center, Oklahoma, OK, USA. [Oaknin A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Romero I] Instituto Valenciano de Oncología, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Int J Gynecol Cancer
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Immunoconjugates, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, BEVACIZUMAB, Medicaments antineoplàstics - Ús terapèutic, Carcinoma, Ovarian Epithelial, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Polyethylene Glycols, 03 medical and health sciences, 0302 clinical medicine, 3211 Oncology and carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, TOPOTECAN, Oncology & Carcinogenesis, Original Research, Ovarian Neoplasms, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, 3202 Clinical sciences, Obstetrics & Gynecology, CHEMOTHERAPY, Ovaris - Càncer - Tractament, 3. Good health, ovarian cancer, Oncology, Doxorubicin, Drug Resistance, Neoplasm, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, TRIAL, Female, WEEKLY PACLITAXEL, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms, Life Sciences & Biomedicine

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36564099
https://hdl.handle.net/11351/9375
https://lirias.kuleuven.be/handle/20.500.12942/714632
https://doi.org/10.1136/ijgc-2022-003927